Anticoagulant-associated intracerebral hemorrhage
Brain Hemorrhages · 2020-03 · 1 (1) · 89-94
DOI: 10.1016/j.hest.2020.01.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Hemorrhages, 2020-03. Verfasst von Andrea Morotti und 1 weiteren Autor:innen. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Intracerebral hemorrhage (ICH) is the most dangerous complication of oral anticoagulant treatment (OAT). Up to half of patients with OAT-related ICH experience early clinical deterioration due to active bleeding, leading to hematoma enlargement. Prevention of ICH expansion is therefore one of the primary goals of acute ICH treatment. Blood pressure control and rapid reversal of coagulopathy are the mainstays of acute medical management. Specific reversal agents for vitamin K antagonists, direct thrombin inhibitors, and Factor Xa inhibitors are now available for clinical use, and may improve outcomes when given early enough in the clinical course.
Zitieren
APA
Morotti, A., & Goldstein, J. N. (2020). Anticoagulant-associated intracerebral hemorrhage. Brain Hemorrhages, 1(1), 89-94. https://doi.org/10.1016/j.hest.2020.01.001
Vancouver
Morotti A, Goldstein JN. Anticoagulant-associated intracerebral hemorrhage. Brain Hemorrhages. 2020;1(1):89-94. doi:10.1016/j.hest.2020.01.001
BibTeX
@article{Morotti2020,
author = {Morotti, Andrea and Goldstein, Joshua N.},
title = {Anticoagulant-associated intracerebral hemorrhage},
journal = {Brain Hemorrhages},
year = {2020},
volume = {1},
number = {1},
pages = {89--94},
doi = {10.1016/j.hest.2020.01.001}
}
EUVIMED